Durvalumab plus tremelimumab for advanced hepatocellular carcinoma is associated with a neutrophil/lymphocyte ratio

被引：0

作者：

Sugimoto, Rie ^{[1
]}

Senjyuu, Takeshi ^{[2
]}

Aratake, Yoshifusa ^{[3
]}

Kuwano, Akifumi ^{[4
]}

Ueda, Akihiro ^{[5
]}

Nakamura, Tsukasa ^{[6
]}

Goya, Takeshi ^{[7
]}

Morita, Yuusuke ^{[1
]}

Tanaka, Yuki ^{[1
]}

Kojima, Motoyuki ^{[3
]}

Tanaka, Masatake ^{[7
]}

机构：

[1] NHO Kyushu Canc Ctr, Dept Hepatobiliary Pancreatol, Fukuoka, Japan

[2] Kyushu Rosai Hosp, Kitakyushu, Fukuoka, Japan

[3] NHO Kyusyu Med Ctr, Fukuoka, Japan

[4] Iizuka Hosp, Iizuka, Fukuoka, Japan

[5] Saiseikai Fukuoka Gen Hosp, Fukuoka, Japan

[6] Fukuoka City Hosp, Fukuoka, Japan

[7] Kyushu Univ, Dept Med & Bioregulatory Sience, Fukuoka, Japan

来源：

CANCER SCIENCE | 2025年 / 116卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-2184

引用

页码：963 / 963

页数：1

共 50 条

[31] Neutrophil to Lymphocyte Ratio and Platelet to Lymphocyte Ratio in Hepatocellular Carcinoma Treated with Stereotactic Body Radiotherapy
Park, Younghee
Chang, Ah Ram
KOREAN JOURNAL OF GASTROENTEROLOGY, 2022, 79 (06): : 252 - 259
[32] Durvalumab plus tremelimumab in biologically selected advanced/metastatic solid tumors
De la Fouchardiere, Christelle
Gomez-Roca, Carlos A.
De Montfort, Aymeric
Italiano, Antoine
Gilabert, Marine
Tredan, Olivier
Korakis, Iphig Nie
Ray-Coquard, Isabelle Laure
Rochefort, Pauline
Dufresne, Armelle
Cousin, Sophie
Le Tourneau, Christophe
You, Benoit
Bertucci, Francois
Cassier, Philippe Alexandre
Attignon, Vale Prime Ry
Mayet, Romaine
Garin, Gwenaelle
Perol, David
Blay, Jean-Yves
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[33] Pretreatment Neutrophil-to-Lymphocyte Ratio as a Predictive Marker of Response to Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma
Eso, Yuji
Takeda, Haruhiko
Taura, Kojiro
Takai, Atsushi
Takahashi, Ken
Seno, Hiroshi
CURRENT ONCOLOGY, 2021, 28 (05) : 4157 - 4166
[34] Durvalumab and tremelimumab for hepatocellular carcinoma in patients listed for a liver transplant.
Sohal, Davendra
Moreland, Katie
Quillin, Ralph
Lemon, Kristina
Rojan, Adam
Olowokure, Olugbenga Olanrele
Shah, Shimul
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS638 - TPS638
[35] Phase Ib trial of durvalumab plus tremelimumab in combination with particle therapy in advanced hepatocellular carcinoma patients with macrovascular invasion: DEPARTURE trial.
Koroki, Keisuke
Makishima, Hirokazu
Wakatsuki, Masaru
Takahashi, Asahi
Kanzaki, Hiroaki
Kobayashi, Kazufumi
Inoue, Masanori
Kiyono, Soichiro
Nakamura, Masato
Kanogawa, Naoya
Kondo, Takayuki
Nakamoto, Shingo
Shiko, Yuki
Ozawa, Yoshihito
Inaba, Yosuke
Kurokawa, Tomoya
Hanaoka, Hideki
Yamada, Shigeru
Kato, Naoya
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 480 - 480
[36] Phase Ib trial of durvalumab plus tremelimumab in combination with particle therapy in patients with advanced hepatocellular carcinoma with macrovascular invasion: DEPARTURE trial.
Koroki, Keisuke
Ogasawara, Sadahisa
Makishima, Hirokazu
Wakatsuki, Masaru
Takahashi, Asahi
Kanzaki, Hiroaki
Kobayashi, Kazufumi
Inoue, Masanori
Kiyono, Soichiro
Nakamura, Masato
Kanogawa, Naoya
Kondo, Takayuki
Nakamoto, Shingo
Shiko, Yuki
Ozawa, Yoshihito
Inaba, Yosuke
Kurokawa, Tomoya
Hanaoka, Hideki
Yamada, Shigeru
Kato, Naoya
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (23_SUPPL) : 34 - 34
[37] Initial treatment efficacy and safety of durvalumab plus tremelimumab combination therapy in unresectable hepatocellular carcinoma in clinical practice
Tomonari, Tetsu
Tani, Joji
Sato, Yasushi
Tanaka, Hironori
Morishita, Akihiro
Okamoto, Koichi
Kawano, Yutaka
Sogabe, Masahiro
Miyamoto, Hiroshi
Takayama, Tetsuji
JGH OPEN, 2024, 8 (10):
[38] Neutrophil-to-lymphocyte ratio is associated with survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib
Tada, Toshifumi
Kumada, Takashi
Hiraoka, Atsushi
Michitaka, Kojiro
Atsukawa, Masanori
Hirooka, Masashi
Tsuji, Kunihiko
Ishikawa, Toru
Takaguchi, Koichi
Kariyama, Kazuya
Itobayashi, Ei
Tajiri, Kazuto
Shimada, Noritomo
Shibata, Hiroshi
Ochi, Hironori
Yasuda, Satoshi
Toyoda, Hidenori
Fukunishi, Shinya
Ohama, Hideko
Kawata, Kazuhito
Nakamura, Shinichiro
Nouso, Kazuhiro
Tsutsui, Akemi
Nagano, Takuya
Itokawa, Norio
Hayama, Korenobu
Arai, Taeang
Imai, Michitaka
Joko, Kouji
Koizumi, Yohei
Hiasa, Yoichi
LIVER INTERNATIONAL, 2020, 40 (04) : 968 - 976
[39] Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
Lau, George
Abou-Alfa, Ghassan K.
Cheng, Ann-Lii
Sukeepaisarnjaroen, Wattana
Kang, Yoon Koo
Dao, Tu Van
Thungappa, Satheesh Chiradoni
Kudo, Masatoshi
Sangro, Bruno
Kelley, Robin Kate
Furuse, Junji
Park, Joong-Won
Sunpaweravong, Patrapim
Fasolo, Angelica
Yau, Thomas
Kawaoka, Tomokazu
Azevedo, Sergio
Reig, Maria
Assenat, Eric
Yarchoan, Mark
He, Aiwu Ruth
Makowsky, Mallory
Gupta, Charu
Negro, Alejandra
Chan, Stephen L.
JOURNAL OF HEPATOLOGY, 2025, 82 (02)
[40] Initial clinical experience with durvalumab plus tremelimumab in patients with unresectable hepatocellular carcinoma in real-world practice
Shimose, Shigeo
Saeki, Issei
Tomonari, Tetsu
Ito, Takanori
Tani, Joji
Takeuchi, Yasuto
Yoshioka, Naoki
Naito, Takehito
Takeuchi, Mamiko
Kakizaki, Satoru
Hatanaka, Takeshi
Sasaki, Kyo
Yasunaka, Tetsuya
Sakata, Masahiro
Iwamoto, Hideki
Itano, Satoshi
Shirono, Tomotake
Tanabe, Norikazu
Yamamoto, Takafumi
Naganuma, Atsushi
Nishina, Soji
Otsuka, Motoyuki
Kawashima, Hiroki
Takayama, Tetsuji
Takami, Taro
Kawaguchi, Takumi
ONCOLOGY LETTERS, 2024, 28 (02)

← 1 2 3 4 5 →